Reference proteins to improve Core 1 and Core 2 Alzheimer’s disease CSF and plasma biomarkers

Concentration-based fluid biomarkers represent an informative and cost-effective way to detect and monitor Alzheimer's disease (AD) pathology. However, non-AD-related inter-individual variation in biofluids can also affect biomarker concentrations. Here, we investigated whether normalization of cerebrospinal fluid (CSF) and plasma biomarkers to reference proteins, such as amyloid-β40 (Aβ40) and non-phosphorylated mid-region tau (np-tau), improves their robustness and reliability of representing AD pathology load. Using the Swedish BioFINDER-2 cohort (n=1702, 50.7% male, mean [SD] age 68.4 [12.2] years), we compared the associations between tau/Aβ-PET load and fluid biomarkers alone versus in a ratio with a reference protein (Aβ40 or np-tau) in univariate linear regression models. Fluid biomarkers included CSF and plasma measures of p-tau217, p-tau181, p-tau205, np-tau181-190, np-tau195-210, np-tau212-221, Aβ42, Aβ40, and CSF MTBR-tau243, SNAP-25, neurogranin, YKL-40, sTREM2, and plasma eMTBR-tau243. Biomarkers were measured with mass spectrometry assays and/or immunoassays. In addition, we performed validation and extended analyses, comparing for example group-level diagnostic differences and longitudinal biomarker trajectories, in three independent prospective cohorts: BioFINDER-1, Knight Alzheimer Disease Research Center (ADRC), and Translational Biomarkers in Aging and Dementia (TRIAD), as well as in an Italian multiple sclerosis cohort. CSF Aβ40 normalization significantly strengthened the associations of several core CSF AD biomarkers, including CSF MTBR-tau243, p-tau isoforms and synaptic biomarkers, with tau-PET (ΔR²=0.064-0.24) and Aβ-PET (ΔR² = 0.016-0.28). Normalization to CSF np-tau mainly improved concordance with Aβ-PET (ΔR² = -0.0059-0.19). The strongest association with tau-PET was observed for MTBR-tau243/Aβ40 (R² = 0.78, compared to 0.65 for non-normalized MTBR-tau243), and with Aβ-PET for p-tau217/np-tau (R² = 0.65, compared to 0.46 for non-normalized p-tau217). Plasma biomarker associations with tau-PET improved when using normalization to plasma Aβ40 or np-tau (ΔR² = 0.004-0.14), with the strongest effect for eMTBR-tau243/np-tau (R² = 0.72 versus 0.60). Associations with Aβ-PET were enhanced with np-tau normalization (ΔR² = 0.018-0.16, strongest for p-tau217/np-tau: R² = 0.62 versus 0.53). The results were replicated in Knight ADRC and TRIAD. Furthermore, longitudinal analyses showed that Aβ40 normalization typically reduced inter-individual rather than intra-individual variability over time. Normalization did not enhance group-level differences in inflammatory CSF biomarkers in AD, nor did it improve biomarker associations in the multiple sclerosis cohort. In conclusion, normalization of CSF and plasma biomarkers to reference proteins, such as Aβ40 or np-tau, enhances their association with brain tau and Aβ pathology, making already high-performing AD fluid biomarkers even more accurate.

Authors

Institutions

Publication Details

Journal
Brain
Published
2025-10-03
DOI
https://doi.org/10.1093/brain/awaf375
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Reference proteins to improve Core 1 and Core 2 Alzheimer’s disease CSF and plasma biomarkers

Tammie L.S. Benzinger, Joseph Therriault, Ann Brinkmalm, Alexa Pichet Binette et al.
Brain
Dementia and Cognitive Impairment Research
article

Reference proteins to improve Core 1 and Core 2 Alzheimer’s disease CSF and plasma biomarkers

Tammie L.S. Benzinger, Joseph Therriault, Ann Brinkmalm, Alexa Pichet Binette, Lucilla Parnetti, Randall John Bateman, Sebastian Palmqvist, Erik Stomrud, Kaj Blennow, Niklas Mattsson, Oskar Hansson, Massimiliano Di Filippo, Gemma Salvadó, Cyrus A. Raji, Kalle Åström, Giovanni Bellomo, Johanna Nilsson, Suzanne E. Schindler, Shorena Janelidze, Jacob W. Vogel, Kanta Horie, Lorenzo Gaetani, Brian A. Gordon, Pedro Rosa‐Neto, Linda Karlsson, Ida Arvidsson, Nicolas R Barthélemy
article en

Abstract

Concentration-based fluid biomarkers represent an informative and cost-effective way to detect and monitor Alzheimer's disease (AD) pathology. However, non-AD-related inter-individual variation in biofluids can also affect biomarker concentrations. Here, we investigated whether normalization of cerebrospinal fluid (CSF) and plasma biomarkers to reference proteins, such as amyloid-β40 (Aβ40) and non-phosphorylated mid-region tau (np-tau), improves their robustness and reliability of representing AD pathology load. Using the Swedish BioFINDER-2 cohort (n=1702, 50.7% male, mean [SD] age 68.4 [12.2] years), we compared the associations between tau/Aβ-PET load and fluid biomarkers alone versus in a ratio with a reference protein (Aβ40 or np-tau) in univariate linear regression models. Fluid biomarkers included CSF and plasma measures of p-tau217, p-tau181, p-tau205, np-tau181-190, np-tau195-210, np-tau212-221, Aβ42, Aβ40, and CSF MTBR-tau243, SNAP-25, neurogranin, YKL-40, sTREM2, and plasma eMTBR-tau243. Biomarkers were measured with mass spectrometry assays and/or immunoassays. In addition, we performed validation and extended analyses, comparing for example group-level diagnostic differences and longitudinal biomarker trajectories, in three independent prospective cohorts: BioFINDER-1, Knight Alzheimer Disease Research Center (ADRC), and Translational Biomarkers in Aging and Dementia (TRIAD), as well as in an Italian multiple sclerosis cohort. CSF Aβ40 normalization significantly strengthened the associations of several core CSF AD biomarkers, including CSF MTBR-tau243, p-tau isoforms and synaptic biomarkers, with tau-PET (ΔR²=0.064-0.24) and Aβ-PET (ΔR² = 0.016-0.28). Normalization to CSF np-tau mainly improved concordance with Aβ-PET (ΔR² = -0.0059-0.19). The strongest association with tau-PET was observed for MTBR-tau243/Aβ40 (R² = 0.78, compared to 0.65 for non-normalized MTBR-tau243), and with Aβ-PET for p-tau217/np-tau (R² = 0.65, compared to 0.46 for non-normalized p-tau217). Plasma biomarker associations with tau-PET improved when using normalization to plasma Aβ40 or np-tau (ΔR² = 0.004-0.14), with the strongest effect for eMTBR-tau243/np-tau (R² = 0.72 versus 0.60). Associations with Aβ-PET were enhanced with np-tau normalization (ΔR² = 0.018-0.16, strongest for p-tau217/np-tau: R² = 0.62 versus 0.53). The results were replicated in Knight ADRC and TRIAD. Furthermore, longitudinal analyses showed that Aβ40 normalization typically reduced inter-individual rather than intra-individual variability over time. Normalization did not enhance group-level differences in inflammatory CSF biomarkers in AD, nor did it improve biomarker associations in the multiple sclerosis cohort. In conclusion, normalization of CSF and plasma biomarkers to reference proteins, such as Aβ40 or np-tau, enhances their association with brain tau and Aβ pathology, making already high-performing AD fluid biomarkers even more accurate.

Brain
University of Science and Technology of China (CN), Statistics Sweden (SE), Montreal Neurological Institute and Hospital (CA), Lund University (SE), Washington University in St. Louis (US), University of Perugia (IT), Sahlgrenska University Hospital (SE), Sorbonne Université (FR), Southwestern Medical Center (US), Mallinckrodt (United States) (US), Pasqual Maragall Foundation (ES), Pitié-Salpêtrière Hospital (FR), Institut Universitaire de Gériatrie de Montréal (CA), Barcelonaβeta Brain Research Center (ES), Skåne University Hospital (SE), Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal (CA), Eisai (United States) (US), Institut du Cerveau (FR), Centres Intégré Universitaires de Santé et de Services Sociaux (CA), Eisai (Japan) (JP), Université de Montréal (CA), The University of Texas Southwestern Medical Center (US), University of Gothenburg (SE)
Alzheimer's Association, Foundation for Barnes-Jewish Hospital, Cure Alzheimer's Fund, Fondation Brain Canada, Weston Brain Institute, EU Joint Programme – Neurodegenerative Disease Research, Consortium canadien en neurodégénérescence associée au vieillissement, GHR Foundation, European Commission, Lunds Universitet, Eisai, Hjärnfonden, Knut och Alice Wallenbergs Stiftelse, Vetenskapsrådet, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Science for Life Laboratory, Skånes universitetssjukhus, Fondation pour la Recherche sur Alzheimer, National Institutes of Health, Parkinsonfonden, Avid Radiopharmaceuticals, Canadian Institutes of Health Research, Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University in St. Louis, Fonds de Recherche du Québec - Santé
Openalex Percentile: Top 66%
Dementia and Cognitive Impairment Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.